// App-Quantinova.ai

1182 : Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1‐6 and Recent Drug Use

Researchers

Presenter

  • Graham R. Foster

Principal Investigators

  • Jason Grebely

  • Kenneth E. Sherman

  • Stanley Wang

  • Gregory J. Dore

  • Axel Baumgarten

  • Brian Conway

  • Daniel F. Jackson

  • Shearwood McClelland

  • Tarik Asselah

  • Michael Gschwantler

  • Krzysztof Tomasiewicz

  • Humberto I. Aguilar

  • Negar Niki Alami

  • Emily O. Dumas

  • Yiran Hu

  • Federico J. Mensa

Medical Centers

  • Queen Mary University of London, London, United Kingdom

  • Kirby Institute, UNSW Sydney, Sydney, NSW, Australia

  • Digestive Diseases, University of Cincinnati College of Medcine, Cincinnati, OH

  • AbbVie, Inc., North Chicago, IL

  • Center for Infectiology Berlin, Berlin, Germany

  • Vancouver Infectious Diseases Centre, Vancouver, BC, Canada

  • Digestive Health Specialists of the Southeast, Dothan, AL

  • Université Paris Diderot, AP‐HP Hôpital Beaujon, Clichy, France

  • Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria

  • Medical University of Lublin, Lublin, Poland

  • Louisiana Research Center, Shreveport, LA

Locations

  • United Kingdom

  • Australia

  • United States

  • Germany

  • Canada

  • France

  • Austria

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis C

Biomarkers

  • N/A

Drug/Treatment

  • Glecaprevir and Pibrentasvir

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved